Diabetes & Bariatrics Completed Research

The TrialNet Type 1 Diabetes Protocol TN-22, Hydroxychloroquine for Prevention of Abnormal Glucose Tolerance and Diabetes in Individuals At-Risk for Type 1 Diabetes Mellitus, describes the background, design, and organization of the study. The protocol will be maintained by the TrialNet Coordinating Center (TNCC) over the course of the study through new releases of the entire protocol, or issuance of updates either in the form of revisions of complete chapters or pages thereof, or in the form of supplemental protocol memoranda.

Project Details
Principal Investigator: Dr Danijela Tatovic
Study Completion: 01/12/2024
Local Ref: 4374

The TrialNet Type 1 Diabetes Protocol TN-18, CTLA-4 Ig (Abatacept) for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At-Risk for Type 1 Diabetes Mellitus, describes the background, design, and organisation of the study. The protocol will be maintained by the TrialNet Coordinating Centre (TNCC) over the course of the study through new releases of the entire protocol, or issuance of updates either in the form of revisions of complete chapters or pages thereof, or in the form of supplemental protocol memoranda.

Project Details
Principal Investigator: Dr Danijela Tatovic
Study Completion: 31/07/2021
Local Ref: 3456

A 78 week comparing the effect and safety of once weekly NNC0148-0287 (insulin 287) and once daily glargine 100 units/mL, both with or without non-insulin antidiabetic treatment, insulin naive subjects with type 2 diabetes

Project Details

Principal Investigator: TBC
Study Completion:14/04/2021
Local Ref: 4841

The treatment of Type 1 and Type 2 diabetes is very different. People with Type 1 diabetes rapidly stop making their own insulin, so need insulin injections from diagnosis. People with Type 2 diabetes can keep making their own insulin but it may not work as well as it should, so they can be treated with diet or tablets. While they may eventually need insulin treatment it is usually not until many years after diagnosis.

It is often difficult for doctors to tell which kind of diabetes a person has, particularly in younger adults where both Type 1 and Type 2 diabetes are common. Because of this, sometimes (in about 15-20% of young adults) people are given the wrong diagnosis. This can have a huge impact as it means they could receive the wrong treatment. A person incorrectly diagnosed with Type 1 diabetes will be prescribed unnecessary insulin injections and miss out on other helpful therapies. A person incorrectly diagnosed with Type 2 diabetes may develop severely high glucose and become unwell with a condition called Diabetic Ketoacidosis if they do not receive insulin treatment.

This study aims to improve this situation by helping doctors more accurately tell the type of diabetes a person has when they are first diagnosed. We will recruit 1000 participants who have recently been diagnosed with diabetes between the ages of 18 and 50 plus 400 aged > 50 at the time of diagnosis and insulin treated. We will record clinical features and measure blood tests that may help us determine diabetes type at diagnosis and follow participants for 3 years to see whether they stop producing their own insulin and need insulin treatment, which confirms Type 1 diabetes. We will assess whether clinical features and blood tests can help us tell if a patient needs rapid insulin treatment and should be initially treated as Type 1 or Type 2 diabetes. We will combine results from this study and existing previous studies to produce a calculator, called a clinical probability model that will allow doctors and patients to combine information from clinical features and (where necessary) blood tests to accurately diagnose what type of diabetes a person has and therefore give the correct treatment. This will be freely available to doctors and patients as a website calculator and smartphone app.

Project Details
Principal Investigator: Dr Angus Jones
Study Completion: 01/08/2020
Local Ref: 3845

The Impact of the Combination of the GLP-1 Analogue Liraglutide (Victoza®) and Laparoscopic Adjustable Gastric Banding (LAGB) on Diabetes Control.

Project Details
Principal Investigator: Dr Dimitri Pournaras
Study Completion: 30/09/2020
Local Ref: 4417